Ceforanide
A second-generation cephalosporin antibiotic used for the treatment of lower respiratory, urinary, skin, and bone infections caused by susceptible organisms. It has a relatively long half-life for its class, allowing twice-daily dosing. It is no longer widely used in clinical practice and has been largely replaced by newer antibiotics.
Molecular Weight
519.6000 g/mol
LogP
-3.20
TPSA
244.00 Ų
Lipinski RO5
Fail
Mechanism of Action
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D Structure
Cite this structure
Embed this structure
SMILES
NCc1ccccc1CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3CC(=O)O)CS[C@H]12
InChI
InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
Molecular Formula
C20H21N7O6S2
HBD / HBA
4 / 12
Rotatable Bonds
10
Heavy Atoms
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A second-generation cephalosporin antibiotic used for the treatment of lower respiratory, urinary, skin, and bone infections caused by susceptible organisms. It has a relatively long half-life for its class, allowing twice-daily dosing. It is no longer widely used in clinical practice and has been largely replaced by newer antibiotics.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceforanide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201046. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 43507. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceforanide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceforanide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceforanide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceforanide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceforanide"></drugfyi-drug>